IN SILICO STUDIES ON NEW INDAZOLE DERIVATIVES AS GSK-3β INHIBITORS

  • Namachivayam Balakrishnan St. Joseph’s College
  • Joseph Santhana Raj Department of Chemistry, St. Joseph’s College, Tiruchirappalli, Tamilnadu, India
  • Naresh Kandakatla Sathayabama University

Abstract

Objective: In silico studies were conducted on newly proposed Indazole derivatives as GSK-3β inhibitors to select the best possible drug candidates based on drug properties and bioactivity score of the compounds.

Methods: 31 Indazole derivatives and active GSK-3β Indazole inhibitor 3-(5-chloro-1-methyl-indol-3-yl)-4-[1-[3-(triazol-1-yl)propyl]indazol-3-yl]pyrrole-2,5-dione(IC50 of 0.003 μM) were subjected to predict the mutagenic, tumorigenic, irritant, reproductive risks, and drug-relevant properties using OSIRIS Property Explorer. Further bioactivity scores were determined using Molinspiration online tools.

Results: The results of new GSK-3β inhibitors were compared with potent GSK-3β Indazole inhibitor to examine the prospective of the optimized compounds. The best possible drug candidates were reported after comprehensive analysis on predicted cLogP, solubility, molecular weight, topological molecular polar surface area (TPSA), drug- likeness, drug score properties and bioactivity score for different human targets like GPCR, ion channel, kinase, nuclear receptor, protease and enzymes.

Conclusion: Five compounds 282, 141, 161, 108 and 456 were reported as the best drug like candidates for GSK-3β regulation.

 

Keywords: Physiochemical properties, GSK-3β, Bioactivity score, Indazole

Downloads

Download data is not yet available.
Statistics
133 Views | 254 Downloads
How to Cite
Balakrishnan, N., J. S. Raj, and N. Kandakatla. “IN SILICO STUDIES ON NEW INDAZOLE DERIVATIVES AS GSK-3β INHIBITORS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 11, 1, p. 425, https://innovareacademics.in/journals/index.php/ijpps/article/view/9233.
Section
Erratum